{"id":912092,"date":"2025-11-20T08:24:23","date_gmt":"2025-11-20T13:24:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/"},"modified":"2025-11-20T08:24:23","modified_gmt":"2025-11-20T13:24:23","slug":"evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/","title":{"rendered":"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <b>Evaxion\u2019s AI-Immunology\u2122 platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models\u00a0<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Evaxion\u2019s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen demonstrates superior performance compared to the traditional gB antigen, including enhanced CMV neutralization<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Preclinical advancement is ongoing with continued optimization and investigation of AI-derived antigens <\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>CMV remains an area of huge unmet medical need. Despite decades of research, no CMV vaccine has been approved to date, underscoring the importance of these new discoveries<\/b><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, November 20, 2025 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, is successfully advancing its novel multi-component cytomegalovirus (CMV) vaccine program, EVX-V1, with new data demonstrating protective effects of lead antigens in the program.<\/p>\n<p align=\"justify\">With our AI-Immunology\u2122 platform, we have uncovered novel antigens that are entirely new to the CMV vaccine research field. These previously unexplored CMV-antigens induce specific immune responses, inhibit viral infection and reduce cell-to-cell spread in cellular and animal viral infection models. These are significant discoveries since very few protective CMV-antigens have been identified despite decades of intensive research.<\/p>\n<p align=\"justify\">The new findings add to earlier data demonstrating that Evaxion\u2019s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen effectively neutralizes CMV. This enhanced gB antigen constitutes a key component of EVX-V1, which combines AI-discovered antigens with AI-optimized conventional antigens to attack the virus from multiple, complementary angles. This broader multi-targeted strategy is expected to strengthen the protective potential of the future vaccine.<\/p>\n<p align=\"justify\">\u201cWe are very excited by the new data demonstrating the unique capability of AI-Immunology\u2122 to find novel protective vaccine targets where no others have been able to do so. This further exemplifies how our technology enables the discovery of potentially groundbreaking new therapies and offers hope for improved prevention of CMV infections, an area of significant medical need\u201d, says Birgitte R\u00f8n\u00f8, CSO and interim CEO of Evaxion.<\/p>\n<p align=\"justify\">Evaxion continues the preclinical advancement of the EVX-V1 program with further identification, investigation and optimization of antigens. In parallel, Evaxion is actively exploring strategic partnerships to accelerate development and ensure a seamless transition into non-clinical and clinical phases.<\/p>\n<p align=\"justify\">\n        <b>About cytomegalovirus (CMV)<\/b><br \/>\n        <br \/>About 1 in 200 babies is born with congenital CMV infection. About 1 in 5 babies with the infection will have congenital disabilities or other long-term health problems. CMV infects approximately 60% to 70% of adults in developed countries and nearly 100% in developing economies, driving demand for CMV treatment. Despite decades of research, no CMV vaccine has been approved to date.<\/p>\n<p align=\"justify\">CMV treatment market size was valued at $474.6 million in 2023 and is anticipated to register an annual growth (CAGR) of 6.6% between 2024 and 2032. This growth is propelled by increasing awareness and prevalence of CMV infection and the development of new and effective treatments.<\/p>\n<p align=\"justify\">CMV is the most complex of all herpes viruses and is a widespread infection transmitted in body fluids. Once infected, the virus stays for life. People with weakened immune systems, including organ transplant patients, can develop severe symptoms affecting, for example, eyes, lungs, and liver, and congenitally infected babies may suffer from intellectual disability and loss of vision and hearing.<\/p>\n<p align=\"justify\">\n        <b>Contact information<\/b>\u00a0<br \/>Evaxion A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=peXFT3Z5FKs_b_k28QHdrlTU5p8lW4LUK19xpYvtatnwAmlFGcnYYb0ypugYW58D8VV2KphJHw5XsCmX8pp-2Q==\" rel=\"nofollow\" target=\"_blank\">mak@evaxion.ai<\/a><\/p>\n<p align=\"justify\">\n        <b>About Evaxion<\/b><br \/>\n        <br \/>Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology\u2122. Evaxion\u2019s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology\u2122, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients\u2019 lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology\u2122 platform and vaccine pipeline, please <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zRV7o8apXrzp6Y8JGuvZrTMMrDYsBdLIH1bonlEOrufYJjCBmqVsxhthpLO1z8cCh9XjQMKJQncrMps9u0feCGfeT6rFPXYlhDoT5qbd75s=\" rel=\"nofollow\" target=\"_blank\">visit our website<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward-looking statement<\/b>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geopolitical and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the US Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n3aOfMdgtioyq-e8J_Tj4Ol5HsRtKwEv4YHQBOThhPBLMo9T0x-mwet4E6xNWAr6xMXS4e3Y46Eq55bKYjVLTEqQ4pk0Vl7M_3M-fSozZ3hcFqZCoPJ6LkFEFdK6qk5IWFAYNSXMc50ZCmb89Jaxl4saPuYX5iGhN-KOOMDIQUO_s6oyvihnjkdAS68Ie_v2zrF5zH8uh7CalfMavdu7r4TqLmnifleiUBphdmdPfB0=\" rel=\"nofollow\" target=\"_blank\"><b>www.sec.gov<\/b><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MTI1YmE1NzUtNDNlMi00ZTBkLThjZjEtNjU4ZGQ0NTFhMDU5LTEyNjM2NDAtMjAyNS0xMS0yMC1lbg==\/tiny\/Evaxion.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Evaxion\u2019s AI-Immunology\u2122 platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models\u00a0 EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens Evaxion\u2019s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen demonstrates superior performance compared to the traditional gB antigen, including enhanced CMV neutralization Preclinical advancement is ongoing with continued optimization and investigation of AI-derived antigens CMV remains an area of huge unmet medical need. Despite decades of research, no CMV vaccine has been approved to date, underscoring the importance of these new discoveries COPENHAGEN, Denmark, November 20, 2025 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, is successfully &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-912092","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Evaxion\u2019s AI-Immunology\u2122 platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models\u00a0 EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens Evaxion\u2019s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen demonstrates superior performance compared to the traditional gB antigen, including enhanced CMV neutralization Preclinical advancement is ongoing with continued optimization and investigation of AI-derived antigens CMV remains an area of huge unmet medical need. Despite decades of research, no CMV vaccine has been approved to date, underscoring the importance of these new discoveries COPENHAGEN, Denmark, November 20, 2025 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, is successfully &hellip; Continue reading &quot;Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-20T13:24:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1\",\"datePublished\":\"2025-11-20T13:24:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/\"},\"wordCount\":932,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/\",\"name\":\"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==\",\"datePublished\":\"2025-11-20T13:24:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 - Market Newsdesk","og_description":"Evaxion\u2019s AI-Immunology\u2122 platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models\u00a0 EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens Evaxion\u2019s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen demonstrates superior performance compared to the traditional gB antigen, including enhanced CMV neutralization Preclinical advancement is ongoing with continued optimization and investigation of AI-derived antigens CMV remains an area of huge unmet medical need. Despite decades of research, no CMV vaccine has been approved to date, underscoring the importance of these new discoveries COPENHAGEN, Denmark, November 20, 2025 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, is successfully &hellip; Continue reading \"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-20T13:24:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1","datePublished":"2025-11-20T13:24:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/"},"wordCount":932,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/","name":"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==","datePublished":"2025-11-20T13:24:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzOTk3MCM0MDIyNjg0NzcjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-positive-data-for-lead-antigens-in-cytomegalovirus-cmv-vaccine-program-evx-v1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/912092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=912092"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/912092\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=912092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=912092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=912092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}